(Q33403311)

English

The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

1

object named as

Julie M Vose

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bruce D. Cheson

4

object named as

Bruce D Cheson

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Edmund K Waller

3

object named as

Edmund K Waller

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Jonathan W Friedberg

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vasthala Juvvigunta

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Holger Fritsch

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Claude Petit

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gerd Munzert

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anas Younes

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

4 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

708-713

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Targeted therapy in lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Targeted anti-mitotic therapies: can we improve on tubulin agents?

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.729833

21 January 2018

Identifiers

10.3109/10428194.2012.729833

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33403311&oldid=2012180021"